TAP vs ZBIO · rev $13.04B vs rev $10.0M
TAP (TAP) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
TAP (TAP) common stock.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported TAP revenue for 2025-12-31 was $13.04B. Net income was -$2.14B. Revenue was down 5.1% from 2024-12-31 to 2025-12-31. TAP currently screens at market cap $0.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
TAP currently screens at market cap $0. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the TAP and ZBIO stock pages for the full models.
Not investment advice.